Sirolimus has “a much wider” safety window and shows fewer local effects than paclitaxel

Paclitaxel kills the cells in the artery wall; sirolimus simply stuns them. So says Peter Gaines (Sheffield, UK) at VLF 2019 while commenting on the modes of action of these two agents that have been used in drug-coated devices in both the coronary and peripheral vessels. Sirolimus is likely to have fewer systemic problems [than paclitaxel] and is much less likely to have local toxic effects on the arteries, he says.

Gaines, Peter

Peter Gaines (Sheffield, UK) is an Honorary Professor at Sheffield Hallam University and was previously President of the British Society of Interventional Radiology (BSIR).

Add comment

Editor’s Peripheral Pick

    Subscribeto receive the very best in medical videos